ARVN Stock Summary and Trading Ideas (Arvinas | NASDAQ:ARVN)

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Arvinas trades on the NASDAQ stock market under the symbol ARVN.

As of October 8, 2026, ARVN stock price climbed to $7.51 with 985,125 million shares trading.

ARVN has a beta of 1.43, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.13 to the broad based SPY ETF.

ARVN has a market cap of $491.05 million. This is considered a Small Cap stock.

Last quarter Arvinas reported $250 million in Revenue and $2.58 earnings per share. This beat revenue expectation by $193 million and exceeded earnings estimates by $2.84.

In the last 3 years, ARVN traded as high as $53.08 and as low as $5.90.

The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, IWM, VXF, IWN, FESM.

ARVN has underperformed the market in the last year with a price return of -19.2% while the SPY ETF gained +16.8%. ARVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.6% and -4.1%, respectively, while the SPY returned +3.8% and +0.8%, respectively.

ARVN support price is $7.21 and resistance is $7.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.